PMD-026 is under clinical development by Phoenix Molecular Designs and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMD-026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PMD-026 overview

PMD-026 is under development for the treatment of triple-negative breast cancer, metastatic breast cancer, ER positive human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer) and castration-resistant prostate cancer. It is a small molecule administered through oral route. The drug candidate acts by targeting ribosomal s6 kinases RSK1 and RSK2.

Phoenix Molecular Designs overview

Phoenix Molecular Designs (PhoenixMD) is a cancer therapy developer that offers the development of kinase inhibitors and advanced breast cancer therapeutics. The company’s kinase inhibitors are cancer drug targets that prevent and kill the growth of cancer cells. It also offers designs precise cancer therapeutics, and provides research and development of RSK inhibitors that kills triple-negative breast cancer cells. PhoenixMD also performs companion diagnostics a test that matches the genetic composition of a drug with that of an individual’s tumor. PhoenixMD is headquartered in Vancouver, British Columbia, Canada .

For a complete picture of PMD-026’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.